TITLE

Evaluation of Saliva as an Alternative Matrix for Monitoring Plasma Zidovudine, Lamivudine and Nevirapine Concentrations in Rwanda

AUTHOR(S)
Gras, Alain; Schneider, Serge; Karasi, Jean-Claude; Ternes, Anne-Marie; Sauvageot, Nicolas; Karasi-Omes, Christine; Henry, Anne-Pascale; Schmit, Jean-Claude; Seguin-Devaux, Carole; Arendt, Vic
PUB. DATE
June 2011
SOURCE
Current HIV Research;Jun2011, Vol. 9 Issue 4, p223
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Saliva may provide interesting advantages as matrix for compliance measurements, pharmacokinetic studies and therapeutic drug monitoring in resource limited countries. We investigated the feasibility of using saliva for compliance monitoring of zidovudine (ZDV), lamivudine (3TC) and nevirapine (NVP) in 29 HIV-1 infected patients from Rwanda. ZDV, 3TC and NVP drug levels were quantified by an LC/MS-MS method in plasma and stimulated saliva samples and compared using Bland-Altman analysis. Seven patients demonstrated undetectable saliva ZDV levels while five out of these seven also showed no 3TC salivary concentrations. For the other samples, we observed a good agreement between salivary and plasma concentrations of each antiretroviral drug. A significant relation between the difference in saliva and plasma ZDV concentrations and the average ZDV concentration in the two matrices was deduced as follows: y = -380.15 + 1.79 x. The log saliva and plasma concentration difference of both 3TC and NVP was consistent across the range of average log concentration. Overall, we showed large agreement limits suggesting a wide inter patient variability that may result in non-reliable plasma level predictions from saliva drug measurements. Therefore, our results indicate that saliva may serve as a valuable tool only for NVP compliance testing because of its high salivary concentration.
ACCESSION #
69600136

 

Related Articles

  • Comparison of Nevirapine Plasma Concentrations between Lead-In and Steady-State Periods in Chinese HIV-Infected Patients. Huijuan Kou; Xiaoli Du; Yanling Li; Jing Xie; Zhifeng Qiu; Min Ye; Qiang Fu; Yang Han; Zhu Zhu; Taisheng Li // PLoS ONE;Jan2013, Vol. 8 Issue 1, Special section p1 

    Objectives: To investigate the potential of nevirapine 200 mg once-daily regimen and evaluate the influence of patient characteristics on nevirapine concentrations. Methods: This was a prospective, multicentre cohort study with 532 HIV-infected patients receiving nevirapine as a part of their...

  • Therapeutic Drug Monitoring of Indinavir in H IV-Infected Patients Undergoing HAART. Langmann, P.; Zilly, M.; Weißbrich, B.; Desch, S.; Väth, T.; Klinker, H. // Infection;Feb2002, Vol. 30 Issue 1, p13 

    Background: Therapeutic drug monitoring (TDM) of protease inhibitors (PI) is gaining increasing importance for the management of HIV-infected patients undergoing highly active antiretroviral. therapy (HAART). The PI indinavir (IDV) is widely used in HAART regimens. Combinations of IDV with...

  • Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals. Laura Dickinson; Marta Boffito; David J. Back; Saye H. Khoo; Anton L. Pozniak; Peter Mugyenyi; Concepta Merry; Reshma Saskia Autar; David M. Burger; Leon J. Aarons // Journal of Antimicrobial Chemotherapy (JAC);Dec2008, Vol. 62 Issue 6, p1344 

    : Objectives The aim of this study was to develop and validate a population pharmacokinetic model in order to describe ritonavir-boosted saquinavir concentrations dosed twice and once daily in human immunodeficiency virus (HIV)-infected patients from the UK, Uganda and Thailand and to identify...

  • Lopinavir Plasma Levels in Salvage Regimes by a Population of Highly Active Antiretroviral TherapyTreated HIV-1–Positive Patients. Torti, C.; Quiros-Roldan, E.; Tirelli, V.; Regazzi-Bonora, M.; Moretti, F.; Pierotti, P.; Orani, A.; Maggi, P.; Cargnel, A.; Patroni, A.; De Luca, A.; Carosi, G. // AIDS Patient Care & STDs;Nov2004, Vol. 18 Issue 11, p629 

    Increased lopinavir (LPV) exposure obtained in vivo through combination with low-dose ritonavir may overcome a certain grade of resistance but not all. We sought to analyze LPV variability and possible risk factors. LPV trough plasma concentrations were determined by highperformance liquid...

  • Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in HIV-Infected Nigerian Adults. Fehintola, Fatai A.; Scarsi, Kimberly K.; Qing Ma; Parikh, Sunil; Morse, Gene D.; Taiwo, Babafemi; Akinola, Ibrahim Tope; Adewole, Isaac F.; Lindegardh, Niklas; Phakderaj, Aphiradee; Ojengbede, Oladosu; Murphy, Robert L.; Akinyinka, Olusegun O.; Aweeka, Francesca T. // AIDS Research & Treatment;2012, p1 

    Background. Nevirapine- (NVP-) based antiretroviral therapy (ART) and artesunate-amodiaquine are frequently coprescribed in areas of HIV and malaria endemicity. We explored the impact of this practice on artesunate and dihydroartemisinin pharmacokinetics. Methods. We conducted a parallel-group...

  • Resistance Patterns Selected by Nevirapine vs. Efavirenz in HIV-Infected Patients Failing First-Line Antiretroviral Treatment: A Bayesian Analysis. Ngo-Giang-Huong, Nicole; Jourdain, Gonzague; Amzal, Billy; Sang-a-gad, Pensiriwan; Lertkoonalak, Rittha; Eiamsirikit, Naree; Tansuphasawasdikul, Somboon; Buranawanitchakorn, Yuwadee; Yutthakasemsunt, Naruepon; Mekviwattanawong, Sripetcharat; McIntosh, Kenneth; Lallemant, Marc // PLoS ONE;2011, Vol. 6 Issue 11, p1 

    Background: WHO recommends starting therapy with a non-nucleoside reverse transcriptase inhibitor (NNRTI) and two nucleoside reverse transcriptase inhibitors (NRTIs), i.e. nevirapine or efavirenz, with lamivudine or emtricitabine, plus zidovudine or tenofovir. Few studies have compared...

  • The antiretroviral efficacy of highly active antiretroviral therapy and plasma nevirapine concentrations in HIV-TB co-infected Indian patients receiving rifampicin based antituberculosis treatment.  // AIDS Research & Therapy;2011, Vol. 8, p41 

    The article reports on a study conducted to assess the efficacy of nevirapine-containing highly active antiretroviral treatment (HAART) when co-administered with rifampicin-containing antituberculosis treatment (ATT). The study also measures plasma nevirapine concentrations in HIV-tuberculosis...

  • Improved antiretroviral treatment outcome in a rural African setting is associated with cART initiation at higher CD4 cell counts and better general health condition. Mossdorf, Erik; Stoeckle, Marcel; Mwaigomole, Emmanuel G.; Chiweka, Evarist; Kibatala, Patience L.; Geubbels, Eveline; Urassa, Honoraty; Abdulla, Salim; Elzi, Luigia; Tanner, Marcel; Furrer, Hansjakob; Hatz, Christoph; Battegay, Manuel // BMC Infectious Diseases;2011, Vol. 11 Issue 1, p98 

    Background: Data on combination antiretroviral therapy (cART) in remote rural African regions is increasing. Methods: We assessed prospectively initial cART in HIV-infected adults treated from 2005 to 2008 at St. Francis Designated District Hospital, Ifakara, Tanzania. Adherence was assisted by...

  • What's new in HIV treatment? Deresinski, Stan // AIDS Alert;12/1/2011, p139 

    The article offers information on the changes made for "Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents," which was published on October 14, 2011, wherein, the updated version focuses on the regimen for antiretroval treatment for HIV patients.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics